Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 278
Filtrar
1.
Pak J Pharm Sci ; 30(5(Special)): 1851-1855, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29084657

RESUMO

This paper aims to compare and analyze clinical efficacy of azithromycin and pefloxacin in treatment of acute enteritis. The 160 patients with acute enteritis were randomly divided into a study group (n=80) treated with azithromycin, and a reference group (n=80) treated with pefloxacin. We compared overall treatment efficiency (markedly, effective, invalid), clinical symptoms and signs remission time (antipyretic time, antidiarrheal time, symptoms and signs disappearance time), interleukin-6 and C-reactive protein concentration before and after treatment, adverse reactions rate (nausea, abdominal pain, headache, etc.). In comparison of overall treatment efficiency of the two groups, the results showed that the study group was significantly superior to the reference group (P<0.05). In comparison of clinical symptoms and signs remission time of the two groups, the study group were significantly shorter than the reference group (P<0.05). At the same time, in comparison of levels of interleukin-6 and C-reactive protein concentration after treatment, the study group was significantly superior to the reference group (P<0.05). There was no significant difference between the two groups in incidence of adverse reactions (P<0.05). The efficacy of azithromycin for acute enteritis is better than that of pefloxacin, and it can significantly reduce clinical symptom remission time. Moreover, safe and reliable, it has great value in clinical application.


Assuntos
Azitromicina/uso terapêutico , Enterite/tratamento farmacológico , Pefloxacina/uso terapêutico , Adulto , Idoso , Antibacterianos/uso terapêutico , Azitromicina/efeitos adversos , Proteína C-Reativa/metabolismo , Enterite/sangue , Enterite/metabolismo , Feminino , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Pefloxacina/efeitos adversos , Fatores de Tempo , Adulto Jovem
2.
Artigo em Francês | MEDLINE | ID: mdl-23827273

RESUMO

UNLABELLED: Rhinoscleroma is a chronic granulomatous respiratory tract disease. The initial lesion site is often intra-nasal. Giant tumor presentations are rare. The authors report a case of extensive nasal rhinoscleroma. OBSERVATION: A 35-year-old African male patient consulted for a large tumor of the nose. The tumor had appeared 25 years before; the initial lesion site was intra-nasal. It presented as a small non-obstructive growth. The tumor was removed 20 years before, and recurred in an exophytic presentation. The main tumor was associated to peripheral, peri-nasal, and upper lip nodules. There was a central granuloma, bleeding on contact. Nasal obstruction was complete. The histological and bacteriological examination of a biopsy specimen confirmed the diagnosis of rhinoscleroma. Trimethoprim-sulfamethoxazole was effective on the infection. DISCUSSION: Rhinoscleroma is frequently located on the nasal mucosa, but extra-nasal giant tumor presentations are rare. It can involve the whole respiratory tract. It is endemic in developing countries. Sporadic cases have been described in non-endemic areas, among migrants. The diagnosis is proved by histology. Specific and early antibiotic therapy is effective. It avoids surgical mutilation, sequels, and recurrence.


Assuntos
Rinoscleroma/diagnóstico , Adulto , Anti-Infecciosos/uso terapêutico , Progressão da Doença , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/terapia , Klebsiella pneumoniae/fisiologia , Masculino , Obstrução Nasal/cirurgia , Nariz/cirurgia , Pefloxacina/uso terapêutico , Procedimentos de Cirurgia Plástica , Rinoscleroma/etiologia , Rinoscleroma/patologia , Rinoscleroma/terapia , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
3.
Med Sci Monit ; 18(3): BR95-102, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22367122

RESUMO

BACKGROUND: The purpose of the current study is to evaluate the effects of systemic ornidazole (SO) and systemic and local compound ornidazole and pefloxacin mesylate (SCOPM/LCOMP) on the inflammatory response associated with rat experimental chronic periodontitis (ECP) in sites with subgingival debridement. MATERIAL/METHODS: Periodontitis was induced in male Sprague-Dawley rats by placing a thin steel ligature around the upper first molars and inoculating them with Porphyromonas gingivalis 381. After the successful induction of the rat ECP, the periodontitis rats were randomly divided into 3 different combined treatment groups: (A) SO with scaling and root planing (SRP); (B) SCOMP with SRP; and (C) LCOMP with SRP. After 2 weeks the effects of the treatments were evaluated based on gingivitis, plaque index, probing pocket depth, aspartate aminotransferase, alveolar bone loss, and hematoxylin-eosin staining of the region around the first molars. RESULTS: After treatment, comparison with ECP was performed. The mean percentage reductions of SBI in SO, SCOPM, and LCOPM were 27.73%, 33.61%, and 58.82%, respectively. Those of PI were 33.20%, 42.80%, and 60.00%; those of PPD were 48.66%, 55.70%, and 72.48%; those of GCF-AST were 41.64%, 49.03%, and 66.42%; and those of ABL were 41.19%, 43.63%, and 54.47%, respectively. The inflammatory score of H&E showed median scores of 2.5, 1.75, 1.63, and 0.95 for ECP, SO, SCOMP, and LCOMP, respectively. All 3 treatment groups exhibited significantly reduced inflammation indicators (P<0.05). Of the 3, group C was the most effective (P<0.05). CONCLUSIONS: Although all the combined treatment groups responded to therapy with significant resolution of the infection, adjunctive LCOMP therapy is more effective for periodontitis.


Assuntos
Ornidazol/uso terapêutico , Pefloxacina/uso terapêutico , Periodontite/tratamento farmacológico , Animais , Masculino , Ornidazol/administração & dosagem , Pefloxacina/administração & dosagem , Periodontite/microbiologia , Porphyromonas gingivalis/patogenicidade , Ratos , Ratos Sprague-Dawley
4.
Clin Lymphoma Myeloma ; 8(6): 359-62, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19064402

RESUMO

Schnitzler's syndrome is characterized by chronic urticaria and monoclonal immunoglobulin (Ig) M gammopathy, with other features including intermittent fever, joint and/or bone pain with radiologic evidence of osteosclerosis, lymphadenopathy, enlarged liver and/or spleen, leukocytosis, and elevated erythrocyte sedimentation rate. The etiology of the syndrome remains obscure, although involvement of various cytokines has been proposed. Bone metabolism and angiogenesis markers are deregulated in Waldenström macroglobulinemia and IgM monoclonal gammopathy of unknown significance, but these markers have not been assessed in Schnitzler's syndrome. Herein, we report a patient with Schnitzler's syndrome who was treated with oral pefloxacin. Serum levels of osteoclast regulators, markers of bone remodeling and angiogenesis cytokines, were measured before treatment and serially after the initiation of treatment. High bone turnover and strikingly elevated levels of angiogenic cytokines were observed at diagnosis. Treatment with pefloxacin resulted in a normalization of the bone remodeling process and a significant reduction of angiogenic cytokines, with rapid and sustained improvement of symptoms, suggesting that these factors might be implicated in the pathophysiology of this syndrome. Furthermore, pefloxacin was proven to be an effective treatment for patients with Schnitzler's syndrome.


Assuntos
Indutores da Angiogênese/metabolismo , Osteogênese , Pefloxacina/uso terapêutico , Síndrome de Schnitzler/tratamento farmacológico , Anti-Infecciosos/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Síndrome de Schnitzler/fisiopatologia
5.
Arch Dermatol ; 143(8): 1046-50, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17709664

RESUMO

BACKGROUND: Schnitzler syndrome is characterized by chronic urticarial rash and monoclonal IgM gammopathy and is sometimes associated with periodic fever, arthralgias, and bone pain. Current treatment is unsatisfactory. OBSERVATIONS: Eleven patients with Schnitzler syndrome were treated with oral pefloxacin mesylate (800 mg/d). In 10 patients, we observed a dramatic and sustained improvement of urticarial and systemic manifestations. Corticosteroid therapy could be stopped or reduced in 6 patients. In 9 patients, pefloxacin was administered for more than 6 months (

Assuntos
Anti-Infecciosos/uso terapêutico , Pefloxacina/uso terapêutico , Síndrome de Schnitzler/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Infecciosos/administração & dosagem , Estudos de Coortes , Quimioterapia Combinada , Glucocorticoides/administração & dosagem , Humanos , Pessoa de Meia-Idade , Pefloxacina/administração & dosagem , Estudos Retrospectivos , Resultado do Tratamento
6.
Medicina (Kaunas) ; 43(4): 291-300, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17485956

RESUMO

BACKGROUND: Acute pancreatitis is a potentially serious condition. It carries an overall mortality rate of 10-15%. Infectious complications account for approximately 80% of deaths from acute pancreatitis, and the question arises whether or not prophylactic antibiotics are useful in the prevention of these complications. Therefore, we performed an evidence-based analysis to assess the effect of available prophylactic antimicrobial treatment on the development of infected necrosis and sepsis, need for surgery, and mortality. METHODS: A comprehensive PubMed search was performed evaluating the value of prophylactic administration of parenteral antibiotics in patients with acute necrotizing pancreatitis. Only articles published in English language between January 1990 and May 2006 were included. The search strategy initially generated 692 articles related to antibiotics in the treatment of acute pancreatitis. This number was reduced to 97 publications related to clinical trials on the same topic. Finally, 10 randomized clinical trials concerning prophylactic parenteral antibiotics in patients with acute necrotizing pancreatitis were identified. We have performed a meta-analysis using the random-effects model to assess the impact of prophylactic antibiotics on development of infected pancreatic necrosis and sepsis, need for surgery, and overall mortality. RESULTS: Patients with necrotizing acute pancreatitis should receive effective antibiotic prophylaxis (i.e., carbapenems intravenously) to decrease the risk of infected necrosis and sepsis and need of surgery. CONCLUSIONS: While providing new insights into key aspects of antibiotic prophylaxis, this evidence-based analysis highlights the need for further clinical trials regarding the indications for antibiotic prophylaxis.


Assuntos
Antibioticoprofilaxia , Carbapenêmicos/uso terapêutico , Medicina Baseada em Evidências , Pancreatite Necrosante Aguda/complicações , Pancreatite Necrosante Aguda/tratamento farmacológico , Sepse/prevenção & controle , Carbapenêmicos/administração & dosagem , Interpretação Estatística de Dados , Humanos , Imipenem/administração & dosagem , Imipenem/uso terapêutico , Incidência , Injeções Intravenosas , Necrose/prevenção & controle , Razão de Chances , Pâncreas/patologia , Pancreatite Necrosante Aguda/diagnóstico por imagem , Pancreatite Necrosante Aguda/mortalidade , Pancreatite Necrosante Aguda/patologia , Pancreatite Necrosante Aguda/cirurgia , Pefloxacina/administração & dosagem , Pefloxacina/uso terapêutico , Prevalência , Ensaios Clínicos Controlados Aleatórios como Assunto , Risco , Fatores de Risco , Sepse/epidemiologia , Fatores de Tempo , Tomografia Computadorizada por Raios X
7.
Cochrane Database Syst Rev ; (3): CD003597, 2006 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-16856014

RESUMO

BACKGROUND: Uncomplicated acute cystitis is one of the most common bacterial infections in adults. The percentage of women who have at least one episode of acute cystitis is estimated to be between 40% to 50%. Quinolones are recommended for acute cystitis in regions where the level of resistance to other antimicrobials namely co-trimoxazole is high. However the efficacy, safety and tolerance of quinolones needs investigation. OBJECTIVES: To compare the efficacy, safety and tolerance of different quinolones in women with uncomplicated acute cystitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library Issue 3, 2003), MEDLINE (1966 - September 2003), EMBASE (1988 - September 2003), reference lists of articles and abstracts from conference proceedings without language restriction. Reference lists of urology, infectious diseases and nephrology textbooks, review articles and relevant studies. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials comparing two or more different quinolones in women (>/= 16 years) with uncomplicated acute cystitis were selected. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes with 95% confidence intervals (CI). MAIN RESULTS: We identified 11 studies enrolling 7535 women. There were no significant differences in clinical or microbiological efficacy between quinolones. Photosensitivity reactions were more frequently observed for sparfloxacin when compared to ofloxacin. Any adverse event, adverse events causing withdrawal, skin adverse events, photosensitivity reactions were more common for lomefloxacin when compared to norfloxacin. Any adverse event, adverse drug reactions, CNS adverse events were more common for ofloxacin when compared to ciprofloxacin. CNS adverse events and insomnia were more often reported for rufloxacin when compared to pefloxacin. Adverse drug reactions occurred frequently for ofloxacin than levofloxacin. Insomnia was reported more frequently for enoxacin than ciprofloxacin. AUTHORS' CONCLUSIONS: We found no significant differences in clinical or microbiological efficacy between quinolones but some differences in occurrence and spectrum of quinolone safety.


Assuntos
Anti-Infecciosos Urinários/uso terapêutico , Cistite/tratamento farmacológico , Doença Aguda , Adulto , Ciprofloxacina/uso terapêutico , Feminino , Fluoroquinolonas/uso terapêutico , Humanos , Levofloxacino , Norfloxacino/uso terapêutico , Ofloxacino/uso terapêutico , Pefloxacina/uso terapêutico , Quinolonas/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto
9.
Pak J Pharm Sci ; 18(4): 61-4, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16380360

RESUMO

In 28 children, with bacteriologically and/or serologically diagnosed typhoid fever treated at CMH, Rawalpindi in 2003, first one of the three recommended drugs (viz. chloramphenicol, amoxycillin or co-trimoxazole) was given for 7 days for defervescence to occur. In those who failed to respond a second trial of therapy with one of the other two drugs was initiated, after excluding the first drug. A second failure of therapy was taken as an indication to use pefloxacin singly. Finally, 18 (64.3%) cases responded to chloramphenicol or amoxycillin or co-trimoxazole. Pefloxacin was used in 10 (35.7%) cases. The failure rate of treatment with chloramphenicol was 50%, with amoxycillin 71.4% with co-trimoxazole 75% and 0% with pefloxacin. An analysis of the 28 cases revealed that apart from fever (in 100%), splenomegaly (in 82.1%) was the most important clinical indicator to diagnosis. along with absolute eosinopenia (in 71.4%). There were no major complications, except 2 cases with typhoid hepatitis that responded to choramphenicol and co-trimoxazole, respectively. Blood culture grew Salmonella typhi in 7 cases of which 5 (72%) were multi drug resistant S. typhi.


Assuntos
Antibacterianos/uso terapêutico , Pefloxacina/uso terapêutico , Febre Tifoide/tratamento farmacológico , Amoxicilina/efeitos adversos , Amoxicilina/uso terapêutico , Antibacterianos/efeitos adversos , Contagem de Células Sanguíneas , Criança , Pré-Escolar , Cloranfenicol/efeitos adversos , Cloranfenicol/uso terapêutico , Feminino , Humanos , Testes de Função Hepática , Masculino , Pefloxacina/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Febre Tifoide/microbiologia
11.
Prescrire Int ; 13(73): 184-6, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15499700

RESUMO

(1) Rare but well-documented cases of joint damage, with no other identified cause, have been reported in children treated with systemic fluoroquinolones. The joint damage usually resolves gradually after drug withdrawal and are more frequent with pefloxacin. (2) The few available paediatric trials included too few patients to identify rare adverse effects on joints, or to show a causal relationship between treatment and joint damage. (3) In practice, quinolones are an option for children only when the expected benefit outweighs the risk of joint damage. In the rare cases in which fluoroquinolone therapy is justified, ciprofloxacin is the drug of first choice. Pefloxacin should be avoided.


Assuntos
Anti-Infecciosos/uso terapêutico , Fluoroquinolonas/uso terapêutico , Animais , Anti-Infecciosos/efeitos adversos , Cartilagem/patologia , Criança , Contraindicações , Cães , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/efeitos adversos , Humanos , Artropatias/induzido quimicamente , Articulação do Joelho/efeitos dos fármacos , Articulação do Joelho/patologia , Pefloxacina/efeitos adversos , Pefloxacina/uso terapêutico , Resultado do Tratamento
12.
Int J Clin Pharmacol Ther ; 41(6): 267-74, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12816179

RESUMO

The levels of metronidazole and pefloxacin in plasma and tissue penetration of both drugs were studied after prophylactic administration to 7 patients undergoing colorectal surgery. Metronidazole (1,500 mg) and pefloxacin (800 mg) were administered as an intravenous infusion 1 hour before surgery. Mean plasma levels of pefloxacin decreased from 12.92 +/- 4.10 microg/ml at the end of the infusion to 2.18 +/- 1.03 microg/ml at 36 h. These values were above the MIC90 for E. coli (0.125 microg/ml) and E. faecalis (0.5 microg/ml), microorganisms responsible for abdominal infections. Tissue pefloxacin levels were also measured with a range from 0.72 - 7.78 microg/g in subcutaneous cell tissue, from 1.94 - 17.55 microg/g in peritoneum and from 2.76 - 21.99 microg/g in colon wall. Mean plasma concentrations of metronidazole decreased from 39.89 +/- 17.08 microg/ml at the end of the infusion to 2.63 +/- 1.11 microg/ml at 36 h. During this period, concentrations were higher than 2 microg/ml, the MIC90 value for B. fragilis, the anaerobic pathogen more frequently involved in postoperative infections after rectal and colonic surgery. Tissue metronidazole levels ranged from 3.64 - 13.37 microg/g in subcutaneous cell tissue, from 3.26 - 41.66 microg/g in peritoneum and from 6.72 - 43.12 microg/g in colon wall. The AUC/MIC values (efficacy parameter for concentration-dependent killing antibiotics such as pefloxacin and metronidazole) obtained were the following: metronidazole AUC/MIC value for B. fragilis was 173; pefloxacin AUC/MIC values for E. coli and E. faecalis were 941 and 235, respectively. The values of these parameters are higher than the recommended values to ensure efficacy, which means good exposure of the antimicrobials to the microorganisms. In conclusion, the combination of pefloxacin and metronidazole as prophylactic agents to prevent infections in patients undergoing colorectal surgery produce plasma and tissue levels above the MIC values of the main pathogens responsible for this kind of infections.


Assuntos
Antibacterianos/farmacocinética , Antibioticoprofilaxia , Procedimentos Cirúrgicos do Sistema Digestório , Complicações Pós-Operatórias/prevenção & controle , Sepse/prevenção & controle , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Bacteroides fragilis/efeitos dos fármacos , Colo/cirurgia , Combinação de Medicamentos , Enterococcus faecalis/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Feminino , Humanos , Infusões Intravenosas , Masculino , Metronidazol/farmacocinética , Metronidazol/uso terapêutico , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Pefloxacina/farmacocinética , Pefloxacina/uso terapêutico , Reto/cirurgia , Sepse/etiologia , Distribuição Tecidual
13.
Pneumologie ; 56(11): 695-703, 2002 Nov.
Artigo em Alemão | MEDLINE | ID: mdl-12442211

RESUMO

Legionellosis is a relatively rare condition but nevertheless is associated more frequently than many other pathogens with a severe course. Therefore, establishing a diagnosis of Legionellosis remains a challenge. The most significant progress in the diagnosis of Legionellosis is antigen-testing in urine by a rapid immunochromatographic test (ICT). This is an easy to handle bedside test which provides a result within 15 minutes. Sensitivity and specificity reach 80 % and 100 %, respectively. However, the exact place of this test within algorithms of clinical decision making still remains unsettled. Macrolides, doxycycline, fluoroquinolones and ketolides, and possibly also streptogramins are drugs with definitely or most probably sufficient activity against Legionella spp. and, therefore, are appropriate candidates within empirical initial antimicrobial treatment regimen of community-acquired pneumonia. Macrolides and fluoroquinolones should be the drugs of choice for the treatment of established Legionellosis. Oral macrolides should be prefered in patients with mild to moderate pneumonia; within the macrolides, azithromycin has the most favourable profile of activity. Alternatively, ciprofloxacin, levofloxacin and moxifloxacin may be selected. In severe Legionellosis as well as independently of severity in nosocomial legionellosis and immunosuppressed patients, intravenous fluoroquinolones are first choice drugs. Alternatively, azithromycin may be used. Whether a combination treatment including azithromycin or fluoroquinolones with rifampin or azithromycin with fluoroquinolone exert superior activity remains currently unknown.


Assuntos
Doença dos Legionários/diagnóstico , Doença dos Legionários/tratamento farmacológico , Antibacterianos/uso terapêutico , Quimioterapia Combinada/uso terapêutico , Eritromicina/uso terapêutico , Humanos , Pefloxacina/uso terapêutico , Rifampina/uso terapêutico
14.
Antibiot Khimioter ; 47(4): 13-5, 2002.
Artigo em Russo | MEDLINE | ID: mdl-12369138

RESUMO

It was shown that microbial flora isolated from the bronchial secretion of 39 patients with mucoviscidosis in 1999-2001 consisted in one third (32.8%) of S. aureus strains. Evaluation of pefloxacin efficacy in the case of monoinfection and pathogens association revealed potent antistaphylococcal effect of the drug. Positive result was demonstrated in 82.3% cases by the 7th day. Among the side effects dominated arthropathy which disappeared at the period from 3 days to 3 months after drug administration was stopped.


Assuntos
Anti-Infecciosos/uso terapêutico , Fibrose Cística/tratamento farmacológico , Pefloxacina/uso terapêutico , Adolescente , Anti-Infecciosos/efeitos adversos , Brônquios/metabolismo , Brônquios/microbiologia , Criança , Pré-Escolar , Fibrose Cística/microbiologia , Fibrose Cística/mortalidade , Humanos , Pefloxacina/efeitos adversos
15.
Biopharm Drug Dispos ; 23(7): 293-300, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12355580

RESUMO

The plasma levels and tissue penetration of pefloxacin were studied after prophylactic administration to patients undergoing elective biliary surgery. Pefloxacin was administered as a single dose of 800 mg given intravenously as an infusion 1 h before surgery. Over a period of two years, cultures of bile and stone were performed after cholecystectomy in order to find the main pathogens present in the geographical area of the hospital of Txagorritxu (Vitoria, Spain), as well as to test the antimicrobial susceptibility of these bacteria to pefloxacin. Thirty seven per cent of the bile and stone cultures were positive, and 75 different species were isolated. E. coli was the predominant microorganism (25%). Other frequent microorganisms were E. faecium (9.3%), S. epidermidis (6.6%) and Cl. perfringens (6.6%). Most species isolated were susceptible to pefloxacin, with MIC(90) values of 0.125 microg/ml for E. coli, 0.5 microg/ml for S. epidermidis and 1 microg/ml for Cl. perfringens. E. faecium was resistant, with a MIC(90) value of 8 microg/ml but a MIC(50) of 4 microg/ml (intermediate). After pefloxacin infusion, adequate drug plasma levels (>MIC(90)) for the most frequent pathogens were found throughout the procedure. Elimination half-life was estimated as 22.03+/-6.91 h; the area under the concentration-time curve from zero to infinite had a value of 275.07+/-130.02 mg h/l and the values for volume of distribution at steady-state and plasma clearance were 96.48+/-28.65 L and 3.60+/-1.83 l/h, respectively. Bile pefloxacin concentrations generally exceeded the minimum inhibitory concentrations for most relevant pathogens. Drug levels in gallbladder and subcutaneous tissues were also above the MIC(90) for extended periods. Patients were observed daily throughout their hospital stay. This included examination of the surgical wound and recording of body temperature. No cases of anaerobic infection were noted in the study patients. Other constants such as hospitalization stay and time of recuperation were normal for this type of surgery. According to these results, pefloxacin presents many features that make it suitable for use as a therapeutic prophylactic agent, such as its broad spectrum of antimicrobial activity and favorable pharmacokinetic properties.


Assuntos
Antibioticoprofilaxia , Ducto Colédoco/metabolismo , Ducto Colédoco/cirurgia , Pefloxacina/farmacocinética , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibioticoprofilaxia/métodos , Antibioticoprofilaxia/estatística & dados numéricos , Área Sob a Curva , Colecistectomia/estatística & dados numéricos , Ducto Colédoco/efeitos dos fármacos , Feminino , Humanos , Infusões Intravenosas , Masculino , Testes de Sensibilidade Microbiana/métodos , Testes de Sensibilidade Microbiana/estatística & dados numéricos , Pessoa de Meia-Idade , Pefloxacina/administração & dosagem , Pefloxacina/uso terapêutico , Distribuição Tecidual/efeitos dos fármacos , Distribuição Tecidual/fisiologia
16.
West Afr J Med ; 21(4): 302-4, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12665270

RESUMO

In this prospective study, superficial and deep swabs of all open fractures seen at the accident and emergency unit of our hospital between January and June 2000 were taken (before wound debridement was done or anitibiotics commenced). Routine microscopy, culture and sensitivities for aerobic and anaerobic organisms were carried out on these specimens. The organisms were cultured and identified using standard techniques and the antibiotic sensitivity testing was carried out using the disc diffusion method of Stokes. Within six hours of injury, single-organism isolates were commonly found whilst after 48 hours a mixed or poly-microbial organism load were isolated. In 90% of the positive isolates, the organisms isolated form the superficial and the deep swabs were the same. The antibiotic sensitivity pattern of all the isolates shows that pefloxacin, ciprofloxacin and ceftriaxone were more effective compared to cefuroxime and amoxycillin which had substantial resistance to most of the isolates. 41 fractures were followed to union and 4 (9.7%) developed osteomyelitis.


Assuntos
Infecções Bacterianas/microbiologia , Fraturas Expostas/complicações , Infecção dos Ferimentos/microbiologia , Antibacterianos/uso terapêutico , Anti-Infecciosos/uso terapêutico , Infecções Bacterianas/epidemiologia , Ceftriaxona/uso terapêutico , Ciprofloxacina/uso terapêutico , Terapia Combinada , Desbridamento , Países em Desenvolvimento , Farmacorresistência Bacteriana , Serviço Hospitalar de Emergência , Tratamento de Emergência , Fraturas Expostas/terapia , Hospitais de Ensino , Humanos , Testes de Sensibilidade Microbiana , Nigéria/epidemiologia , Osteomielite/epidemiologia , Osteomielite/microbiologia , Seleção de Pacientes , Pefloxacina/uso terapêutico , Estudos Prospectivos , Fatores de Tempo , Infecção dos Ferimentos/epidemiologia
18.
Antibiot Khimioter ; 47(9): 14-7, 2002.
Artigo em Russo | MEDLINE | ID: mdl-12619515

RESUMO

Results of prospective comparative investigation of monofluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin) arthropathy are presented. The trial was performed at 144 children with mucoviscidosis (aged 0.5-16) and at 37 children with aplastic anemia (aged 1.75-15). Two groups differ by necessary antibacterials regimes and hence by different abilities for arthropathy development: patients with mucoviscidosis were treated with fluoroquinolones followed by repeated short courses in combination with other antibacterials; patients with aplastic anemia--were treated permanently for a long time with low doses as monotherapy for autoinfection prophylaxis. Analysis was performed on the base of catamnesis, year growth rate, postmortal morphological investigation of the right knee joint. It was shown that quinolone arthropathy development didn't depend on treatment duration, as it developed during the first three weeks of the fluoroquinolone use, but depended on the drug, patient age and nosology. Arthropathy has favourable prognosis and was fully resolved at the period from 7 days to 3 month according to the arthropathy form (arthrologic, arthritic). Quinolones arthropathy at the children has specific features, the main one is absence of cartilage damage confirmed by morphological analysis.


Assuntos
Fluoroquinolonas/uso terapêutico , Adolescente , Fatores Etários , Anemia Aplástica/tratamento farmacológico , Anti-Infecciosos/uso terapêutico , Estatura/efeitos dos fármacos , Cartilagem/patologia , Criança , Pré-Escolar , Ciprofloxacina/uso terapêutico , Fibrose Cística/tratamento farmacológico , Esquema de Medicação , Feminino , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/efeitos adversos , Humanos , Lactente , Artropatias/induzido quimicamente , Articulação do Joelho/efeitos dos fármacos , Articulação do Joelho/patologia , Masculino , Ofloxacino/uso terapêutico , Pefloxacina/uso terapêutico , Estudos Prospectivos , Resultado do Tratamento
20.
Antibiot Khimioter ; 46(5): 24-7, 2001.
Artigo em Russo | MEDLINE | ID: mdl-11558450

RESUMO

The efficacy of pefloxacin in the complex treatment of 28 patients with pancreatonecrosis of various etiology was estimated in a prospective trial. The diagnosis of pancreatonecrosis was verified by the data of the disease clinical progress, laboratory findings and instrumental examination. Pefloxacin (Abactal; LEK) was administered intravenously in a dose of 400 mg every 8 hours (1200 mg) in combination with metronidazole in a dose of 1.5-2.0 g a day intravenously. When indicated 3 days after the start of the pefloxacin therapy, the treatment was switched to the oral use of the drug in the same dosage. The positive clinical effect (cure and improvement) at the end of the treatment with pefloxacin was stated in 78 per cent of the patients in spite of the initial severity state of above 15 APACHE II. It was shown that in the treatment of patients with pancreatonecrosis when the severity state was not above 12 APACHE II the antibacterial therapy with pefloxacin in combination with metronidazole was optimal.


Assuntos
Anti-Infecciosos/uso terapêutico , Pancreatite Necrosante Aguda/tratamento farmacológico , Pefloxacina/uso terapêutico , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pancreatite Necrosante Aguda/etiologia , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA